Company
Every investor coverage indicates participated in a round SYNthesis Med Chem raised.
Companies SYNthesis Med Chem acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming SYNthesis Med Chem. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Biotech scientist Andrew Wilks launches fund SYNthesis BioVentures, which has gathered $20m and aims for $75m; his group has backed two biotech startups and he earlier sold a chemistry business to Viva Biotech.
Australian diabetes biotech Verva sold all its IP to two biotechs and entered liquidation with PKF Australia appointed; background recalls early Adipogen backing from Uniseed, QIC BioVentures and GBS Ventures.